Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma

Natural killer/T-cell lymphoma (NKTCL) is an Epstein–Barr virus-associated non-Hodgkin lymphoma linked to an aggressive clinical course and poor prognosis. Despite an improvement in survival outcomes with the incorporation of novel agents including immune checkpoint inhibitors in the treatment of NKTCL, a significant proportion of patients still relapse or remain refractory to treatment. Several clinical prognostic models have been developed for NKTCL patients treated in the modern era, though the optimal approach to risk stratification remains to be determined. Novel molecular biomarkers derived from multi-omic profiling have recently been developed, with the potential to improve diagnosis, prognostication and treatment of this disease. Notably, a number of potential biomarkers have emerged from a better understanding of the tumor immune microenvironment and inflammatory responses. This includes a recently described 3′UTR structural variant in the PD-L1 gene, which confers susceptibility to checkpoint immunotherapy. In this review, we summarize the biomarker landscape of NKTCL and highlight emerging biomarkers with the potential for clinical implementation.

[1]  R. Gale,et al.  NK-/T-cell lymphomas , 2021, Leukemia.

[2]  Y. Ko,et al.  EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma , 2021, Scientific Reports.

[3]  C. Ong,et al.  A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma. , 2021, Blood.

[4]  Kyung-Han Lee,et al.  Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping , 2021, Scientific Reports.

[5]  S. Lim,et al.  The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer/T-cell lymphoma , 2021, Annals of Nuclear Medicine.

[6]  C. Ong,et al.  Checkpoint immunotherapy for NK/T cell lymphoma—Time for a showdown? , 2021, Precision clinical medicine.

[7]  Q. Cai,et al.  High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL) , 2021, Expert review of anticancer therapy.

[8]  J. Y. Lee,et al.  Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma , 2020, Cancers.

[9]  Dahai Liu,et al.  High infiltration of CD20+ B lymphocytes in extranodal natural killer/T‐cell lymphoma is associated with better prognosis , 2020, British journal of haematology.

[10]  C. Ong,et al.  Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. , 2020, Blood.

[11]  Dachuan Huang,et al.  Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma , 2020, Leukemia.

[12]  P. Kong,et al.  Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma , 2020, Biomarker Research.

[13]  W. Xu,et al.  Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma , 2020, Annals of Hematology.

[14]  I. Sohn,et al.  Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. , 2020, Blood.

[15]  Jian-yong Li,et al.  Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): Extended follow-up on the multicenter, single-arm phase II trail (ORIENT-4). , 2020 .

[16]  W. Qian,et al.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma , 2020, Translational cancer research.

[17]  Wenwen Guo,et al.  Abnormal expression of p-ATM/CHK2 in nasal extranodal NK/T cell lymphoma, nasal type, is correlated with poor prognosis , 2020, Journal of Clinical Pathology.

[18]  Weili Zhao,et al.  Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. , 2020, Cancer cell.

[19]  R. Tsang,et al.  Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making , 2020, Leukemia.

[20]  Xinmei Yu,et al.  Predicting treatment response of patients with extranodal natural killer/T‐cell lymphoma based on levels of PD‐L1 mRNA and soluble PD‐L1 , 2020, Hematological oncology.

[21]  G. Ma,et al.  KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients. , 2020, Neoplasma.

[22]  Dachuan Huang,et al.  Evaluation of the PIK3 pathway in peripheral T‐cell lymphoma and NK/T‐cell lymphoma , 2020, British journal of haematology.

[23]  P. Wei,et al.  Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type. , 2020, American journal of cancer research.

[24]  Hongbing Shen,et al.  Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. , 2019, The Lancet. Oncology.

[25]  W. Park,et al.  Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression , 2019, Modern Pathology.

[26]  Dachuan Huang,et al.  A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study , 2019, Scientific Reports.

[27]  U. Bunworasate,et al.  Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance , 2019, Acta Haematologica.

[28]  I. Moon,et al.  CD30‐positive cutaneous extranodal natural killer/T‐cell lymphoma: clinicopathological features and survival outcomes , 2018, International journal of dermatology.

[29]  Ying Huang,et al.  A prognostic index for nasal‐type early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study , 2019, American journal of hematology.

[30]  Lei Guo,et al.  The correlation of clinicopathological features and prognosis in extranodal natural killer/T cell lymphoma: a report of 42 cases in the early stage , 2019, Annals of Hematology.

[31]  D. Rossi,et al.  Liquid biopsy in lymphoma , 2019, Haematologica.

[32]  P. Gaulard,et al.  Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas , 2019, Leukemia.

[33]  Y. Ko,et al.  Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma , 2018, Leukemia & lymphoma.

[34]  Jian-yong Li,et al.  Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[35]  B. Zhang,et al.  Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis. , 2019, Human pathology.

[36]  B. Venkatesh,et al.  Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma , 2018, Blood Cancer Journal.

[37]  Wen-Qi Jiang,et al.  Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome , 2018, Annals of Hematology.

[38]  Y. Oki,et al.  Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma , 2018, Front. Oncol..

[39]  C. Ki,et al.  Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma , 2018, Annals of Hematology.

[40]  G. Shen,et al.  Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis , 2018, PloS one.

[41]  K. Young,et al.  Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma , 2018, Journal of Hematology & Oncology.

[42]  S. Lim,et al.  Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas , 2018, International Journal of Hematology.

[43]  Dachuan Huang,et al.  Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. , 2017, Blood.

[44]  Y. S. Lee,et al.  Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  M. Takahara,et al.  Circulating Epstein‐Barr virus–encoded micro‐RNAs as potential biomarkers for nasal natural killer/T‐cell lymphoma , 2017, Hematological oncology.

[46]  Sisi Yu,et al.  Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma , 2017, Oncotarget.

[47]  Xia Li,et al.  Hemoglobin level, a prognostic factor for nasal extranodal natural killer/T-cell lymphoma patients from stage I to IV: A validated prognostic nomogram , 2017, Scientific Reports.

[48]  Sun-Hee Kim,et al.  Macrophage inflammatory protein 1 alpha (MIP‐1α) may be associated with poor outcome in patients with extranodal NK/T‐cell lymphoma , 2017, Hematological oncology.

[49]  P. Khong,et al.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. , 2017, Blood.

[50]  M. Takahara,et al.  Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy , 2017, Cancer Immunology, Immunotherapy.

[51]  Zhaoming Li,et al.  Pretreatment 14‐3‐3 epsilon level is predictive for advanced extranodal NK/T cell lymphoma therapeutic response to asparaginase‐based chemotherapy , 2017, Proteomics. Clinical applications.

[52]  Wen-Qi Jiang,et al.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma , 2016, Journal of Hematology & Oncology.

[53]  D. Heo,et al.  Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis , 2016, Virchows Archiv.

[54]  Y. Okada,et al.  Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. , 2016, The Lancet. Oncology.

[55]  Zhaoming Li,et al.  MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma , 2016, Oncotarget.

[56]  Wen-Qi Jiang,et al.  High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients , 2016, Oncotarget.

[57]  Cheng-Cheng Liu,et al.  Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma , 2016, Oncotarget.

[58]  Hongwei Xue,et al.  DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China , 2016, Clinical Cancer Research.

[59]  Zhaoming Li,et al.  S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine , 2016, Scientific Reports.

[60]  Sin-Ho Jung,et al.  A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[61]  J. Kim,et al.  Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type , 2016, Annals of Hematology.

[62]  Wenqi Jiang,et al.  Oncotargets and Therapy Dovepress Increased Serum Levels of Interleukin-10 Predict Poor Prognosis in Extranodal Natural Killer/t-cell Lymphoma Patients Receiving Asparaginase-based Chemotherapy , 2022 .

[63]  Wen-Qi Jiang,et al.  Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase , 2015, Oncotarget.

[64]  D. Heo,et al.  Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities , 2015, Leukemia & lymphoma.

[65]  Hui-Qiang Huang,et al.  High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type , 2015, Annals of Hematology.

[66]  Seungbok Lee,et al.  Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type , 2015, Oncotarget.

[67]  Wen-Qi Jiang,et al.  The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type , 2015, Annals of Hematology.

[68]  Yu-jing Zhang,et al.  CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type , 2015, Annals of Hematology.

[69]  Yu-jing Zhang,et al.  A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma , 2015, Leukemia & lymphoma.

[70]  T. Wu,et al.  Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study , 2015, Leukemia.

[71]  S. Hyun,et al.  Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. , 2015, The Lancet. Haematology.

[72]  K. Takata,et al.  Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma: A Cellular Lineage and Clinicopathologic Study of 60 Patients From Asia , 2015, The American journal of surgical pathology.

[73]  W. Xue,et al.  Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma , 2014, Nature Genetics.

[74]  Cheng-Cheng Liu,et al.  Increased serum levels of interleukin-15 correlate with negative prognostic factors in extranodal NK/T cell lymphoma , 2015, Medical Oncology.

[75]  Hua Wang,et al.  CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type , 2014, BMC Cancer.

[76]  K. Takata,et al.  Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy , 2014, Cancer science.

[77]  Bei Zhang,et al.  Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type , 2014, Medical Oncology.

[78]  Yingmei Wang,et al.  Tumor-associated macrophages promote tumor cell proliferation in nasopharyngeal NK/T-cell lymphoma. , 2014, International journal of clinical and experimental pathology.

[79]  Y. Ishigatsubo,et al.  Serum ferritin level is prognostic of patient outcome in extranodal NK/T cell lymphoma, nasal type , 2014, Medical Oncology.

[80]  Zhenhuan Zhao,et al.  Association between higher expression of YB-1 and poor prognosis in early-stage extranodal nasal-type natural killer/T-cell lymphoma. , 2014, Biomarkers in medicine.

[81]  K. Young,et al.  New prognostic model for extranodal natural killer/T cell lymphoma, nasal type , 2014, Annals of Hematology.

[82]  Cheng-Cheng Liu,et al.  Serum Levels of Interleukin-9 Correlate with Negative Prognostic Factors in Extranodal NK/T-Cell Lymphoma , 2014, PloS one.

[83]  A. Pang,et al.  Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance , 2014, Leukemia.

[84]  M. Takahara,et al.  Downregulation of miR‐15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T‐cell lymphoma , 2014, American journal of hematology.

[85]  R. Suzuki,et al.  Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group , 2013, Journal of Hematology & Oncology.

[86]  Ding-Zhun Liao,et al.  Clinical significance of serum soluble interleukin-2 receptor-a in extranodal natural killer / T-cell lymphoma ( ENKTL ) : a predictive biomarker for treatment efficacy and valuable prognostic factor , 2013 .

[87]  Jin Zhu,et al.  Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type , 2013, Virchows Archiv.

[88]  Wen-Qi Jiang,et al.  Serum C-Reactive Protein (CRP) as a Simple and Independent Prognostic Factor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type , 2013, PloS one.

[89]  Wen-Qi Jiang,et al.  The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T‐cell lymphoma, nasal type , 2013, American journal of hematology.

[90]  Q. Cai,et al.  Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type , 2010, Advances in hematology.

[91]  Ding-Zhun Liao,et al.  Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor. , 2013, Medical oncology.

[92]  Hui-jun Zhu,et al.  LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphoma, nasal type (ENKTL) , 2012, Diagnostic Pathology.

[93]  Y. Kwong,et al.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. , 2012, Blood.

[94]  Shulian Wang,et al.  Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. , 2012, Blood.

[95]  C. Ong,et al.  Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. , 2012, Cancer discovery.

[96]  Xiangyuan Wu,et al.  High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas , 2012, Medical Oncology.

[97]  K. Sugimoto,et al.  Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL , 2012, Clinical Cancer Research.

[98]  Junshik Hong,et al.  Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. , 2012, International journal of clinical and experimental pathology.

[99]  K. Kawa,et al.  Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. , 2011, Blood.

[100]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  Joy Tan,et al.  Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. , 2011, Blood.

[102]  Elias Campo,et al.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.

[103]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[104]  D. Heo,et al.  MicroRNA-146 a downregulates NF κ B activity via targeting TRAF 6 , and functions as a tumor suppressor having strong prognostic implications in NK / T cell lymphoma , 2011 .

[105]  Chengcheng Guo,et al.  Diagnostic and Prognostic Value of Circulating miR-221 for Extranodal Natural Killer/T-Cell Lymphoma , 2011, Disease markers.

[106]  K. Ohshima,et al.  Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas , 2010, Leukemia & lymphoma.

[107]  Hiroyuki Tagawa,et al.  Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. , 2009, Blood.

[108]  D. Heo,et al.  Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[109]  Xueguang Liu,et al.  NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. , 2009, Japanese journal of clinical oncology.

[110]  D. Weisenburger,et al.  Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. , 2009, Blood.

[111]  C. Ki,et al.  Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma , 2009, Leukemia & lymphoma.

[112]  Baocun Sun,et al.  Expression of LMP-1 and Cyclin D1 protein is correlated with an unfavorable prognosis in nasal type NK/T cell lymphoma. , 2008, Molecular medicine reports.

[113]  C. Choi,et al.  Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  M. Takahara,et al.  Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T‐cell lymphoma , 2007, Journal of medical virology.

[115]  Keunchil Park,et al.  Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  L. Shih,et al.  Nasal NK/T Cell Lymphoma in Taiwan: A Clinicopathologic Study of 22 Cases, with Analysis of Histologic Subtypes, Epstein-Barr Virus LMP-1 Gene Association, and Treatment Modalities , 2004, International journal of surgical pathology.

[117]  W. Au,et al.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. , 2004, Blood.

[118]  P. Johnson,et al.  Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[119]  Y. Natkunam,et al.  Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  D. Arber,et al.  Sinonasal NK/T-cell Lymphomas in the United States , 2000, The American journal of surgical pathology.

[121]  K. Aozasa,et al.  Low frequency of HLA‐A*0201 allele in patients with Epstein‐Barr virus‐positive nasal lymphomas with polymorphic reticulosis morphology , 2000, International journal of cancer.